Affimed N.V.

2.71-0.1300-4.58%Vol 4.36M1Y Perf -65.82%
Jun 24th, 2022 16:00 DELAYED
BID2.66 ASK2.99
Open2.77 Previous Close2.84
Pre-Market- After-Market2.78
 - -  0.07 2.58%
Target Price
10.33 
Analyst Rating
Strong Buy 1.00
Potential %
281.18 
Finscreener Ranking
★★★+     51.22
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     42.40
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     47.33
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.29 
Earnings Rating
Buy
Market Cap404.65M 
Earnings Date
1st Jun 2022
Alpha0.02 Standard Deviation0.34
Beta2.49 

Today's Price Range

2.712.87

52W Range

2.238.81

5 Year PE Ratio Range

-7.90-2.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
9.27%
1 Month
-14.51%
3 Months
-37.84%
6 Months
-54.15%
1 Year
-65.82%
3 Years
1.12%
5 Years
32.20%
10 Years
-

TickerPriceChg.Chg.%
AFMD2.71-0.1300-4.58
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.00
3.10
0.12
0.16
-73.30
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
-
-203.10
-199.50
-457.30
-93.14
RevenueValueIndustryS&P 500US Markets
41.56M
0.28
10.20
67.18
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.18-0.1611.11
Q04 2021-0.17-0.22-29.41
Q03 2021-0.13-0.17-30.77
Q02 2021-0.07-0.19-171.43
Q01 2021-0.080.01112.50
Q04 2020--0.20-
Q03 2020-0.12-0.0833.33
Q02 2020-0.12-0.18-50.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1765.31Positive
9/2022 QR-0.1773.44Positive
12/2022 FY-0.67--
12/2023 FY-0.78--
Next Report Date-
Estimated EPS Next Report-0.18
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume4.36M
Shares Outstanding149.32K
Shares Float144.44M
Trades Count10.44K
Dollar Volume11.94M
Avg. Volume1.38M
Avg. Weekly Volume1.11M
Avg. Monthly Volume1.08M
Avg. Quarterly Volume1.95M

Affimed N.V. (NASDAQ: AFMD) stock closed at 2.71 per share at the end of the most recent trading day (a -4.58% change compared to the prior day closing price) with a volume of 4.36M shares and market capitalization of 404.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Affimed N.V. CEO is Adi Hoess.

The one-year performance of Affimed N.V. stock is -65.82%, while year-to-date (YTD) performance is -50.91%. AFMD stock has a five-year performance of 32.2%. Its 52-week range is between 2.23 and 8.81, which gives AFMD stock a 52-week price range ratio of 7.29%

Affimed N.V. currently has a PE ratio of -3.50, a price-to-book (PB) ratio of 3.02, a price-to-sale (PS) ratio of 8.91, a price to cashflow ratio of 2.00, a PEG ratio of 2.32, a ROA of -32.60%, a ROC of -47.43% and a ROE of -52.82%. The company’s profit margin is -93.14%, its EBITDA margin is -199.50%, and its revenue ttm is $41.56 Million , which makes it $0.28 revenue per share.

Of the last four earnings reports from Affimed N.V., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. Affimed N.V.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Affimed N.V. is Strong Buy (1), with a target price of $10.33, which is +281.18% compared to the current price. The earnings rating for Affimed N.V. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Affimed N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Affimed N.V. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.24, ATR14 : 0.22, CCI20 : -6.10, Chaikin Money Flow : -0.29, MACD : -0.20, Money Flow Index : 38.34, ROC : -8.45, RSI : 44.40, STOCH (14,3) : 50.53, STOCH RSI : 0.81, UO : 51.32, Williams %R : -49.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Affimed N.V. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

CEO: Adi Hoess

Telephone: +49 6221674360

Address: Im Neuenheimer Feld 582, Heidelberg 69120, , DE

Number of employees: 128

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

76%24%

Bearish Bullish

65%35%

TipRanks News for AFMD

Tue, 12 Apr 2022 02:25 GMT Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Zentalis Pharmaceuticals (ZNTL)

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 02:08 GMT Affimed (AFMD) Initiated with a Buy at Leerink Partners

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 12:18 GMT Affimed (AFMD) Receives a Buy from Berenberg Bank

- TipRanks. All rights reserved.

News

Stocktwits